---
layout: default
title: Dexamethasone Phosphate
parent: 僅模型預測 (L5)
nav_order: 163
evidence_level: L5
indication_count: 0
---

# Dexamethasone Phosphate
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Dexamethasone Phosphate: Preliminary Evaluation — Insufficient Data for Assessment

## One-Sentence Summary

Dexamethasone phosphate is a phosphate ester prodrug of dexamethasone, a potent synthetic glucocorticoid corticosteroid widely used for its anti-inflammatory and immunosuppressive properties. The TxGNN model has **not generated any predicted new indications** for this compound, and the evidence pack contains significant data gaps that prevent a meaningful repurposing assessment at this time.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not available in evidence pack |
| Predicted New Indication | None — no TxGNN predictions generated |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 (No predictions or supporting studies) |
| South Africa Market Status | Not marketed (per evidence pack) |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | **Hold** |

## Why is This Prediction Reasonable?

This section cannot be completed as the TxGNN model did not generate any predicted new indications for dexamethasone phosphate.

Currently, detailed mechanism of action data is not available in the evidence pack. Based on established pharmacological knowledge, dexamethasone phosphate is a water-soluble prodrug of dexamethasone — a long-acting fluorinated corticosteroid that acts by binding to intracellular glucocorticoid receptors, modulating gene transcription to suppress inflammatory and immune responses. It is one of the most widely used corticosteroids globally for conditions ranging from inflammatory disorders, allergic reactions, and autoimmune diseases to cerebral oedema, chemotherapy-induced nausea, and as part of COVID-19 treatment protocols (per the RECOVERY trial).

However, since no TxGNN repurposing candidates were generated, no mechanism-based assessment of a new indication can be provided. The absence of predictions may be due to: (1) a failure to map dexamethasone phosphate to a DrugBank ID (noted as `null` in the evidence pack), (2) the compound being a salt/prodrug form not directly represented in the TxGNN knowledge graph, or (3) insufficient linkage between the drug entity and the knowledge graph nodes.

## Clinical Trial Evidence

Currently no related clinical trials registered in the evidence pack. Note that dexamethasone (the parent compound) has extensive global clinical trial data — the absence here reflects a data collection gap rather than true absence of evidence.

## Literature Evidence

Currently no related literature available in the evidence pack.

## South Africa Market Information

No SAHPRA registrations were found in the evidence pack. However, it should be noted that **dexamethasone** (the parent compound) is included on the **South African Essential Medicines List (EML)** and is widely available in South Africa in multiple formulations (oral tablets, injectable solutions, ophthalmic preparations). The absence of registration data here likely reflects a query limitation specific to the "dexamethasone phosphate" salt form rather than true market absence.

## Safety Considerations

> Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.

**Note:** All safety fields (key warnings, contraindications, drug interactions) in the evidence pack are flagged as data gaps. Given that dexamethasone is a well-established medicine, comprehensive safety information is available in standard pharmacological references and the SAHPRA-approved PI documents. Key considerations for dexamethasone include:
- Adrenal suppression with prolonged use
- Immunosuppression and infection risk
- Hyperglycaemia and diabetogenic effects
- Osteoporosis with chronic use
- Multiple significant drug-drug interactions (CYP3A4 substrate)

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The evidence pack contains critical data gaps — no DrugBank ID mapping, no TxGNN predictions, no regulatory data, and no safety information. A meaningful drug repurposing evaluation cannot be conducted without these foundational elements.

**To proceed, the following is needed:**
- **Resolve DrugBank ID mapping**: Dexamethasone phosphate (DrugBank: DB14649) or parent compound dexamethasone (DrugBank: DB01234) should be correctly linked to enable TxGNN knowledge graph predictions
- **Re-run TxGNN prediction pipeline** with the corrected DrugBank mapping to generate repurposing candidates
- **Collect SAHPRA registration data** for dexamethasone and its salt forms available in South Africa
- **Obtain safety data** from the SAHPRA-approved Professional Information (PI) and DrugBank
- **Clarify whether the parent compound (dexamethasone) or the specific salt form (dexamethasone phosphate) is the intended evaluation target**, as the parent compound would yield substantially more knowledge graph connections and prediction candidates

---

*Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing candidates require clinical validation before application. All predictions require further verification through appropriately designed clinical studies.*
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

